3E Bioventures Capital is a healthcare-focused venture capital firm investing in innovative therapeutic drugs, drug discovery platforms, and TechBio innovations. The firm manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and the United States.
62% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 5 prior). Their most common stage is series-a (44% of deals). Average disclosed round size is $49.1M (across 38 rounds with reported amounts).
Portfolio
31
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Team
MM
Maifeng Melford Yuan
Partner
CS
Christine Siying Wu
Investment Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
45 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Arnatar Therapeutics | Series A | $50M | Sep 2026 |
 Lysoway Therapeutics | Series A | $22M | Jun 2026 |
 OncoC4 | Series B | $50M | Oct 2025 |
 Rapafusyn | Series A | $44M | Sep 2025 |
 Arnatar | Series A | $52M | Aug 2025 |
| Arnatar Therapeutics | Series A | $52M | Aug 2025 |
 Acclaro | Series B | $23M | Jun 2025 |
| Rapafusyn | Series A | $44M | Jan 2025 |
 Acclaro Medical | Series B | $23M | Jan 2025 |
| Acclaro | Series B | $23M | Jan 2025 |
| Arnatar Therapeutics | Series A | $52M | Dec 2024 |
| Arnatar | Series A | $52M | Jan 2024 |
 Smartlens | Series A | $6.1M | Jul 2023 |
 Eluminex Biosciences | Series B | — | Feb 2023 |
 Lipidio | Series A | $20M | Nov 2022 |
 Dewpoint Therapeutics | Series C | $150M | Feb 2022 |
 Dermaliq | Series A | $15M | Jan 2022 |
| Arnatar | Seed | — | Jan 2022 |
| DDewpoint | Series C | $150M | Jan 2022 |
 Alebund | Series B | $54.5M | Sep 2021 |
| CCardea | Unknown | $6.5M | Jan 2021 |
 Neural Galaxy | Series A | $77M | Jan 2021 |
| CCardea Bio | Series A | $7.5M | Jan 2021 |
| Alebund | Series B | $60M | Jan 2021 |
 Subtle Medical | Series A | $12.2M | Nov 2020 |
Page 1 of 2
Top Co-Investors
Eight Roads5 shared
Leaps by Bayer4 shared
Maverick Ventures4 shared
Mirae Asset4 shared
General Catalyst4 shared
Timefolio Capital4 shared
Mubadala Ventures4 shared
ARCH Venture Partners4 shared
Samsara BioCapital4 shared
Polaris Partners4 shared
F-Prime Capital4 shared
Gaorong Capital4 shared
Sand Hill Angels4 shared
LAV4 shared
The MBA Fund3 shared
Legend Star3 shared
Accelmed Partners3 shared
Luminous Ventures3 shared
FreeS Fund3 shared
Lightspeed Venture Partners3 shared
Last updated: 20 October 2026